Experience of intravenous calcium treatment and long-term responses to treatment in a patient with hereditary Vitamin D-resistant rickets resulting from a novel mutation


BAYRAMOĞLU E., SAVAŞ ERDEVE Ş., Shi Y., KESKİN M., ÇETİNKAYA S., KURNAZ E., ...Daha Fazla

Journal of Pediatric Endocrinology and Metabolism, cilt.32, sa.6, ss.647-651, 2019 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 32 Sayı: 6
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1515/jpem-2018-0399
  • Dergi Adı: Journal of Pediatric Endocrinology and Metabolism
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.647-651
  • Anahtar Kelimeler: hereditary vitamin D resistant rickets, i.v. calcium treatment, vitamin D receptor mutation
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Vitamin D resistant rickets (HVDRR), is a rare autosomal recessive disorder caused by Vitamin D receptor (VDR) gene mutations. There is no standard treatment in HVDRR. The patient was a 3-year-old girl presenting with short stature, genu varum deformity, waddling gait and alopecia. She had hypocalcemia, hypophosphatemia, hyperparathyroidism and normal 1.25-(OH)2D levels. The patient was initially treated with calcitriol and high-dose oral calcium (Ca) for 22 months. The patient was treated with continuous high dose intravenous (i.v.) Ca therapy for 4 months, following initial lack of response to oral Ca and calsitriol. At the end of the 4 months, rickets was dramatically improved and did not recur for 3 years after i.v. Ca therapy. DNA sequence analyses of the VDR gene showed a homozygous novel mutation. We identified a novel VDR gene mutation, and we concluded that i.v. Ca therapy from the central catheter is a safe treatment in HVDRR.